Cerebral endothelial 3-mercaptopyruvate sulfurtransferase improves ischemia-induced cognitive impairment via interacting with protein phosphatase 2A
The catalytic activity of 3-mercaptopyruvate (3MP) sulfurtransferase (MPST) converts 3MP to hydrogen sulfide (H<sub>2</sub>S). However, the regulatory mechanisms governing MPST and its impact on the brain remain largely unexplored. Our study reveals the neuroprotective role of endothelial MPST-generated H<sub>2</sub>S, regulated by protein phosphatase 2A (PP2A). Bioinformatics analysis and RNA sequencing demonstrated that endothelial PP2A is associated with neurodegenerative disease pathways. Cerebral ischemic mice exhibited significant inactivation of endothelial PP2A, evidenced by the reduction of PP2Ac<i>α</i> in the brain endothelium. Mice with endothelium-specific null PP2A (PP2A<sup>EC-cKO</sup>) exhibited neuronal loss, cognitive dysfunction, and long-term potentiation deficits. Postnatal inactivation of endothelial PP2A also contributes to cognitive dysfunction and neuronal loss. However, regaining endothelial PP2A activity by overexpressing <i>Ppp2ca</i> rescued neuronal dysfunction. Mechanistically, PP2A deficiency is intricately linked to the MPST-H<sub>2</sub>S signaling pathway. A robust reduction in endothelial MPST-dependent H<sub>2</sub>S production followed PP2A deficiency. Exogenous H<sub>2</sub>S treatment and AAV-mediated overexpression of MPST in brain endothelial cells significantly mitigated neuronal dysfunction in PP2A<sup>EC-cKO</sup> mice. Furthermore, PP2A deficiency promotes an increase in calcium influx and calpain2 phosphorylation, subsequently leading to MPST degradation. The PP2A activator (FTY720) and MPST activator (3MP sodium) both remarkably restored endothelial MPST-dependent H<sub>2</sub>S production, subsequently rescuing ischemia-induced neurological deficits. In conclusion, our study demonstrates that endothelial PP2A deficiency leads to MPST degradation by activating calpain2, thus damaging neuronal function.
Authors
- Rongjun Zou (ORCID: https://orcid.org/0000-0003-1981-5472)
- Yong Luo (ORCID: https://orcid.org/0000-0001-9386-5721)
- Ziqing Song
- Wei Wang (ORCID: https://orcid.org/0000-0002-3711-5181)
- Linfeng Dai
- Yang Chen (ORCID: https://orcid.org/0000-0003-0206-1889)
- Qiuhe Chen (ORCID: https://orcid.org/0000-0002-7391-8184)
- Jing Jin (ORCID: https://orcid.org/0000-0001-9726-7323)
- Li Zhu
- Yi Huang (ORCID: https://orcid.org/0000-0002-2220-6216)
- Rui Zuo (ORCID: https://orcid.org/0000-0002-3564-1356)
- Yunting Wang (ORCID: https://orcid.org/0000-0002-9246-4173)
- Minyi Zhang (ORCID: https://orcid.org/0000-0002-2796-0904)
- Rongrong He (ORCID: https://orcid.org/0000-0002-0664-7708)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Jinan University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Guangzhou University (CN)
- First Affiliated Hospital of Jinan University (CN)
- University of Houston (US)
Publication Details
- Journal
- Acta Pharmaceutica Sinica B
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1016/j.apsb.2024.11.015
- Citations
- 4
- Primary Topic
- Mitochondrial Function and Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Natural Science Foundation of China